Mechanism: A stimulus-dependent switch in AP-1 dimer composition, from protective c-Jun/ATF2 to pathological JunB/c-Fos, drives senescence-associated secretory phenotype (SASP). Readout: Readout: A JunB DNA-binding mutant (JunB-DBM) abolishes late IL-6/IL-8 secretion while preserving early protective functions.
It's hypothesized that the transition from early protective JNK‑AP‑1 activity to late‑phase SASP‑driven pathology is caused by a stimulus‑dependent switch in AP‑1 dimer composition from c‑Jun/ATF2 to JunB/c‑Fos, which rewires enhancer binding to favor NF‑κB cooperation and p300‑mediated acetylation at SASP loci.
Mechanistic Model
Early JNK activation (0‑48 h) phosphorylates c‑Jun and ATF2, promoting c‑Jun/ATF2 dimers that bind antioxidant response elements and suppress p53‑dependent senescence 1. As inflammatory cytokines (TNF, IL‑1) accumulate, sustained JNK signaling induces expression of the phosphatase MKP‑1 inhibitor and reduces MKP‑1 activity, prolonging JNK phosphorylation of JunB and c‑Fos. JunB, whose transcription is amplified by IL‑1‑driven NF‑κB 4 5, preferentially pairs with c‑Fos to form JunB/c‑Fos dimers. These dimers exhibit higher affinity for κB‑adjacent AP‑1 sites found in enhancers of IL‑6, IL‑8 and other SASP genes. Co‑occupancy with NF‑κB p65 recruits p300, increasing H3K27ac and stabilizing an open chromatin state that maintains SASP transcription 3.
Predictions and Experimental Design
- Time‑resolved ChIP‑seq for c‑Jun, ATF2, JunB, c‑Fos, p65 and p300 in doxorubicin‑treated MEFs sampled at 0, 12, 24, 48, 72 and 96 h will show a shift from c‑Jun/ATF2‑p300 peaks at antioxidant genes to JunB/c‑Fos‑p65‑p300 peaks at SASP enhancers after 72 h.
- CRISPR‑mediated knock‑in of a JunB DNA‑binding mutant (JunB‑DBM) that cannot dimerize with c‑Fos will preserve early JNK‑dependent ROS suppression but abolish late IL‑6/IL‑8 secretion without affecting p53‑dependent senescence induction.
- Pharmacological inhibition of MKP‑1 (using NSC‑95397) after 48 h will accelerate the JunB/c‑Fos switch and precipitate premature SASP expression, whereas MKP‑1 overexpression will delay the switch and extend the protective window.
Potential Outcomes and Falsifiability
If the ChIP‑seq data reveal no change in AP‑1 dimer occupancy correlating with the transcriptional switch, or if JunB‑DBM cells still show robust SASP secretion, the hypothesis is falsified. Conversely, observation of the predicted dimer exchange, dependence on MKP‑1 activity, and loss of SASP upon JunB‑DBM rescue would support the model.
Comments
Sign in to comment.